Rui Avelar
Chief Tech/Sci/R&D Officer bei EVOLUS, INC.
Vermögen: 5 Mio $ am 31.03.2024
Profil
Rui Avelar is currently the Chief Medical Officer, Head-Research & Development at Evolus, Inc. He previously held the position of Chief Medical Officer at Allergan Medical Optics from 2011 to 2013 and at AEON Biopharma Sub, Inc. from 2014 to 2018.
Dr. Avelar obtained his doctorate degree from the University of Toronto in 1989.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
EVOLUS, INC.
0,61% | 19.03.2024 | 372 288 ( 0,61% ) | 5 Mio $ | 31.03.2024 |
Aktive Positionen von Rui Avelar
| Unternehmen | Position | Beginn |
|---|---|---|
| EVOLUS, INC. | Chief Tech/Sci/R&D Officer | 01.01.2014 |
Ehemalige bekannte Positionen von Rui Avelar
| Unternehmen | Position | Ende |
|---|---|---|
AEON Biopharma Sub, Inc.
 AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA. | Chief Tech/Sci/R&D Officer | 01.02.2018 |
| Allergan Medical Optics | Chief Tech/Sci/R&D Officer | 01.12.2013 |
Ausbildung von Rui Avelar
| University of Toronto | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| EVOLUS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
| Allergan Medical Optics | |
AEON Biopharma Sub, Inc.
AEON Biopharma Sub, Inc. Pharmaceuticals: OtherHealth Technology AEON Biopharma Sub, Inc. is a biopharmaceutical company. It focuses on developing a proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions, with an initial focus on the neurology and gastroenterology markets. The company was founded by Robert E. Grant on February 24, 2012 and is headquartered in Newport Beach, CA. | Health Technology |
